Hugh Wiltshire

2.2k total citations
31 papers, 1.7k citations indexed

About

Hugh Wiltshire is a scholar working on Infectious Diseases, Oncology and Virology. According to data from OpenAlex, Hugh Wiltshire has authored 31 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 13 papers in Oncology and 9 papers in Virology. Recurrent topics in Hugh Wiltshire's work include Drug Transport and Resistance Mechanisms (12 papers), HIV/AIDS drug development and treatment (12 papers) and HIV Research and Treatment (9 papers). Hugh Wiltshire is often cited by papers focused on Drug Transport and Resistance Mechanisms (12 papers), HIV/AIDS drug development and treatment (12 papers) and HIV Research and Treatment (9 papers). Hugh Wiltshire collaborates with scholars based in United Kingdom, United States and Switzerland. Hugh Wiltshire's co-authors include Johan W. Smit, Alfred H. Schinkel, Maarten T. Huisman, Jos H. Beijnen, Olaf van Tellingen, Gary S Tilbrook, Keith M. Borkett, Gavin J. Kilpatrick, Kristel M. L. Crommentuyn and Noam Zelcer and has published in prestigious journals such as Journal of Clinical Investigation, Analytical Biochemistry and The Journal of Infectious Diseases.

In The Last Decade

Hugh Wiltshire

31 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hugh Wiltshire United Kingdom 17 715 507 443 439 241 31 1.7k
Juan J.L. Lertora United States 24 185 0.3× 252 0.5× 222 0.5× 399 0.9× 166 0.7× 49 1.7k
DJ Back United Kingdom 24 354 0.5× 415 0.8× 146 0.3× 347 0.8× 123 0.5× 49 1.5k
María José García Sánchez Spain 20 186 0.3× 341 0.7× 235 0.5× 355 0.8× 83 0.3× 74 1.2k
Manoli Vourvahis United States 21 444 0.6× 277 0.5× 224 0.5× 502 1.1× 262 1.1× 55 1.4k
John Tjia United Kingdom 17 203 0.3× 236 0.5× 177 0.4× 725 1.7× 452 1.9× 23 1.3k
Thomas R. MacGregor United States 19 148 0.2× 151 0.3× 158 0.4× 695 1.6× 487 2.0× 46 1.3k
Kimberly K. Adkison United States 21 606 0.8× 291 0.6× 154 0.3× 404 0.9× 309 1.3× 42 1.7k
D.J. Back United Kingdom 29 388 0.5× 475 0.9× 172 0.4× 596 1.4× 347 1.4× 80 2.2k
A J Wood United States 6 664 0.9× 465 0.9× 60 0.1× 431 1.0× 289 1.2× 7 1.1k
Robin DiFrancesco United States 18 101 0.1× 204 0.4× 137 0.3× 538 1.2× 298 1.2× 53 968

Countries citing papers authored by Hugh Wiltshire

Since Specialization
Citations

This map shows the geographic impact of Hugh Wiltshire's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hugh Wiltshire with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hugh Wiltshire more than expected).

Fields of papers citing papers by Hugh Wiltshire

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hugh Wiltshire. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hugh Wiltshire. The network helps show where Hugh Wiltshire may publish in the future.

Co-authorship network of co-authors of Hugh Wiltshire

This figure shows the co-authorship network connecting the top 25 collaborators of Hugh Wiltshire. A scholar is included among the top collaborators of Hugh Wiltshire based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hugh Wiltshire. Hugh Wiltshire is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wiltshire, Hugh, Carlos V. Payá, Mark D. Pescovitz, et al.. (2005). Pharmacodynamics of Oral Ganciclovir and Valganciclovir in Solid Organ Transplant Recipients. Transplantation. 79(11). 1477–1483. 154 indexed citations
3.
Wiltshire, Hugh, Colm Farrell, Carlos V. Payá, et al.. (2005). Pharmacokinetic Profile of Ganciclovir After its Oral Administration and From its Prodrug, Valganciclovir, in Solid Organ Transplant Recipients. Clinical Pharmacokinetics. 44(5). 495–507. 92 indexed citations
4.
Wiltshire, Hugh, et al.. (2004). Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl. The Pediatric Infectious Disease Journal. 23(3). 263–266. 24 indexed citations
5.
Kurowski, Michael, Charles Oo, Hugh Wiltshire, & Joanne Barrett. (2004). Oseltamivir Distributes to Influenza Virus Replication Sites in the Middle Ear and Sinuses. Clinical Drug Investigation. 24(1). 49–53. 15 indexed citations
6.
Huisman, Maarten T., Johan W. Smit, Kristel M. L. Crommentuyn, et al.. (2002). Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS. 16(17). 2295–2301. 179 indexed citations
7.
Hill, George, Tomáš Cihlář, Charles Oo, et al.. (2002). The Anti-Influenza Drug Oseltamivir Exhibits Low Potential to Induce Pharmacokinetic Drug Interactions via Renal Secretion—Correlation of in Vivo and in Vitro Studies. Drug Metabolism and Disposition. 30(1). 13–19. 99 indexed citations
8.
Wiltshire, Hugh, et al.. (2002). CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavirin vitro. Xenobiotica. 32(1). 1–17. 54 indexed citations
9.
Dewey, Michael J., Hugh Wiltshire, Paul Weigl, et al.. (2001). Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir.. PubMed. 29(3). 299–303. 37 indexed citations
10.
Huisman, Maarten T., Johan W. Smit, Hugh Wiltshire, et al.. (2001). P-Glycoprotein Limits Oral Availability, Brain, and Fetal Penetration of Saquinavir Even with High Doses of Ritonavir. Molecular Pharmacology. 59(4). 806–813. 144 indexed citations
11.
Huisman, Maarten T., Johan W. Smit, Hugh Wiltshire, et al.. (2001). P-Glycoprotein Limits Oral Availability, Brain, and Fetal Penetration of Saquinavir Even with High Doses of Ritonavir. Molecular Pharmacology. 59(4). 806–813. 11 indexed citations
12.
13.
Wiltshire, Hugh, Taryn F. Moy, Steven R. Harris, et al.. (2000). The Disposition of Saquinavir in Normal and P-glycoprotein Deficient Mice, Rats, and in Cultured Cells. Drug Metabolism and Disposition. 28(9). 1058–1062. 82 indexed citations
14.
Wiltshire, Hugh, et al.. (2000). Chromatographic and Immunochemical Approaches to the Analysis of the HIV Protease Inhibitor Saquinavir in Plasma. Analytical Biochemistry. 281(1). 105–114. 15 indexed citations
15.
Smit, Johan W., Maarten T. Huisman, Olaf van Tellingen, Hugh Wiltshire, & Alfred H. Schinkel. (1999). Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. Journal of Clinical Investigation. 104(10). 1441–1447. 264 indexed citations
16.
Wiltshire, Hugh, et al.. (1998). The synthesis of labelled forms of saquinavir. Journal of Labelled Compounds and Radiopharmaceuticals. 41(12). 1103–1126. 13 indexed citations
17.
Pettoello‐Mantovani, Massimo, Tobias R. Kollmann, Christina Raker, et al.. (1998). thy/liv‐SCID‐hu Mice: A System for Investigating the In Vivo Effects of Multidrug Therapy on Plasma Viremia and Human Immunodeficiency Virus Replication in Lymphoid Tissues. The Journal of Infectious Diseases. 177(2). 337–346. 20 indexed citations
18.
Welker, Horst A., Hugh Wiltshire, & Roy Bullingham. (1998). Clinical Pharmacokinetics of Mibefradil. Clinical Pharmacokinetics. 35(6). 405–423. 69 indexed citations
19.
20.
Battersby, Alan R., James Staunton, Hugh Wiltshire, Rawle Francis, & Robert Southgate. (1975). Biosynthesis. Part XXII. The origin of chelidonine and of other alkaloids derived from the tetrahydroprotoberberine skeleton. Journal of the Chemical Society Perkin Transactions 1. 1147–1147. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Juan J.L. Lertora Breakdown of academic impact, for papers by DJ Back Breakdown of academic impact, for papers by María José García Sánchez Breakdown of academic impact, for papers by Manoli Vourvahis Breakdown of academic impact, for papers by John Tjia Breakdown of academic impact, for papers by Thomas R. MacGregor Breakdown of academic impact, for papers by Kimberly K. Adkison Breakdown of academic impact, for papers by D.J. Back Breakdown of academic impact, for papers by A J Wood Breakdown of academic impact, for papers by Robin DiFrancesco
Rankless by CCL
2026